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Abstract
Radiotherapy has conventionally been viewed as immunosuppressive, which has precluded its use in combination with
immunotherapy for prostate and other cancers. However, the relationship between ionizing radiation and immune
reactivity is now known to be more complex than was previously thought, and data on the use of radiotherapy and
immunotherapy are accumulating. Herein, we review this topic in the light of recently available data in the prostate cancer
setting. Recent research has shown no signiﬁcant lymphopenia in patients undergoing radiotherapy for high-risk
adenocarcinoma of the prostate. In addition, emerging evidence suggests that radiotherapy can have immunostimu-
latory effects, and that tumor cell death, coupledwith related changes in antigenavailability and inﬂammatory signals, can
affect lymphocyte and dendritic cell activation. Initial studies have focused on combinations of tumor irradiation and
immunotherapy, such as the autologous cellular immunotherapy sipuleucel-T and the monoclonal antibody ipilimumab,
in metastatic castration-resistant prostate cancer. These combinations appear to have clinical promise, and further
investigation of the potentially synergistic combination of radiotherapy and immunotherapy is continuing in clinical trials.
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Radiotherapy has historically been thought of as immunosup-
pressive and therefore not appropriate for combination with treat-
ments that act on the immune system. However, this view of
radiotherapy might be overly simplistic, and a growing body of
evidence suggests that ionizing radiation can be immunostimula-
tory. This opens up opportunities for combining radiotherapy with
cancer immunotherapies, which are approved or under investigation
for various malignancies including prostate cancer. Clinical data
on the use of radiotherapy with immunotherapy, both together and
sequentially, are accumulating. In this review we consider recent*This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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http://dx.doi.org/10.1016/j.clgc.2014.09.001advances that challenge widely held views, not only on the effects of
radiotherapy but also the potential synergy between radio- and
immunotherapeutic approaches.
Effects of Radiotherapy on the
Immune System
The accepted rationale for using radiotherapy in cancer is under-
pinned by tumor cell death and effects on tumor-associated stroma
caused by DNA damage.1 The conventional view is that rapidly
dividing cancer cells are more sensitive to ionizing radiation than
normal tissue, and therapeutic radiation is therefore applied to induce
apoptosis and other forms of cell death within a deﬁned area while
minimizing toxic effects onnormal tissue around the treatmentﬁeld.1,2
Inevitably, irradiation of living tissue involves damage to that
tissue, whether it is tumor tissue, normal host stroma, normal
host parenchyma, or leukocytes.1 The attenuation of lymphocyte
numbers by radiotherapy, as previously reported in patients un-
dergoing treatment for gynecologic3 or prostate4 malignancies,
might therefore be viewed as an adverse effect. The ultimate
manifestation of this is seen in patients who undergo total body
irradiation (as widely used in conditioning regimens for hemato-
logic malignancies), who experience prolonged pancytopenia.5
Studies have described reductions in numbers of T, B, andClinical Genitourinary Cancer February 2015 - 1
Immunotherapy and Radiotherapy for Prostate Cancer
2 - Clinatural killer (NK) cells, apoptosis or alteration of antigen-
presenting cells (APCs), including dendritic cells (DCs) and mac-
rophages, apoptosis of lymphocytes, and changes to antigen
expression on tumor cells after radiotherapy with doses from
approximately 50 to 70 Gy.3,4,6,7 Localized radiotherapy has
reportedly resulted in signiﬁcant reductions in lymphocyte levels in
stage I to II prostate cancer or locally advanced gynecologic neo-
plasms.3,4 Similarly, studies on radiotherapy in patients with stage I
to III breast cancer have shown lymphopenia, low functional ac-
tivity of NK cells, decreased monocyte phagocytosis, and decreased
tumor necrosis factor (TNF)-a production.7
Observations such as these have contributed to the conven-
tional view of radiation therapy as immunosuppressive, and it has
therefore not been used with cancer immunotherapy. However,
emerging data suggest that standard radiotherapy in high-risk
prostate adenocarcinoma might not be as immunosuppressive as
previously thought, nor the relationship between radiation and
immune responses as straightforward.1,8 The relative contribu-
tions and reactions of systemic and locoregional cell populations
and the differing effects of dose and delivery methods might in-
ﬂuence immune responses via a range of cellular mechanisms
(Figure 1).9Figure 1 Radiation Effects on Immune Cells and Consequent Modul
Induced DNA Damage and Upregulation of the p53 Tumor S
Which Can Induce Ceramide Formation and Activate the S
Expression, Which in Turn Induces MHC and Cytokines via
Class I, Adhesion Molecules, Co-Stimulatory Molecules, H
Cytokines, and Death Receptors
Abbreviations: ATM ¼ Ataxia Telangiectasia Mutated; CD ¼ Cluster of Differentiation; DNA-PK ¼ DNA
Kappa Light Chain Enhancer of Activated B Cells; PKR ¼ Protein Kinase R; SAPK/JNK ¼ Stress-Ac
nical Genitourinary Cancer February 2015Radiotherapy can cause tumor cell apoptosis by inducing DNA
damage, upregulating the p53 tumor suppressor gene, and
through damage to the cellular lipid membrane. This in turn can
lead to ceramide formation and activation of the stress-activated
protein kinases/Jun amino-terminal kinases (SAPK/JNK) sig-
naling pathway. The resultant damage-associated molecular
patterns (apoptotic and necrotic cellular debris) can generate
antigen-speciﬁc immunity through DC maturation and presen-
tation of DC-processed antigen to T cells.9
Activation of the SAPK/JNK signaling pathway and the pres-
ence of damage-associated molecular patterns might also be partly
responsible for other immunological effects seen after radio-
therapy.9 Studies in a variety of tumors have shown that radiation
induces chemokines Chemokine (C-X-C motif) ligand, CXCL10,
and CXCL16, which in turn promote recruitment of effector CD8
and T-helper 1 CD4 T cells.10 Radiation has also been shown to
induce a number of different proinﬂammatory cytokines,
including interleukin (IL) 1b, TNF-a and type 1 and 2 in-
terferons.10 Additionally, in several cancer models, tumor cells
exposed to radiation have been shown to have enhanced expression
of major histocompatibility complex (MHC) class 1 molecules, co-
stimulatory molecules, adhesion molecules (such as intercellularation by Radiotherapy.9 Apoptosis Can Be Initiated by Radiation-
uppressor Gene, and by Damage to the Cellular Lipid Membrane,
APK/JNK Signaling Pathway. SAPK/JNK Can Upregulate PKR
NF-kB. Radiation Treatment Induces Cellular Expression of MHC
eat Shock Proteins, Inﬂammatory Mediators, Immunomodulatory
-Dependent Protein Kinase; MHC ¼ Major Histocompatibility Complex; NF-kB ¼ Nuclear Factor
tivated Protein Kinases/Jun Amino-Terminal Kinases.
Table 1 White Blood Cell Count (WBC) and Absolute Lymphocyte Counts (ALC) at Baseline and After Radiotherapy in 26 Patients With
Adenocarcinoma of the Prostate13
Parameter Statistic Baseline
Days After Radiotherapy
1-90 91-180 181-360 >360
WBC, Cells/mL n 26 18 13 21 20
Mean 6527 5806 6362 6038 6085
Median 6050 5350 6000 5800 5200
Minimum 4000 3500 3500 3400 4400
Maximum 10,100 13,100 11,000 13,100 10,000
ALC, Cells/mL n 21 11 9 10 8
Mean 1680 1054 1059 1246 1275
Median 1700 970 1100 1250 1350
Minimum 700 700 500 590 1000
Maximum 3100 1700 1500 2100 1400
Normal reference ranges were 3800 to 10,700 cells/mL for WBC and 910 to 4280 cells/mL for ALC.
Abbreviation: n ¼ number of observations in an interval.
Figure 2 Median Baseline and Subsequent Cell Counts After
Radiation Therapy.13 (A) White Blood Cell (WBC)
Counts; (B) Absolute Lymphocyte Counts (ALC)
A
B
Abbreviation: AUC ¼ Area Under the Curve.
Steven E. Finkelstein et aladhesion molecule 1 [ICAM-1]), and stress-induced ligands
(including NK Group 2D ligands on NK cells).10,11 Furthermore,
radiation can upregulate expression of the Fas death receptor on
tumor cells, which induces sensitivity of the tumor cells to T-cell
receptor independent, Fas-mediated killing.11 Finally, a direct ef-
fect of radiation on tumors has been reported, in which radio-
therapy modiﬁes the phenotype of tumor cells to render them
more susceptible to vaccine-mediated T-cell killing.12 As a com-
bined result of these mechanisms, radiotherapy can engage both
the innate and adaptive arms of the immune system,9-11 thereby
converting the irradiated tumor into an in-situ “vaccine” that
elicits a tumor-speciﬁc T-cell response, and the inﬁltration of
leukocytes.
A more detailed summary of the effects of radiotherapy on some
of the components of the immune system is described in the
following sections.
Effects of Radiation Therapy on White Blood Cell Counts
in High-Risk Adenocarcinoma of the Prostate
In contrast to observations discussed previously,3,4,6,7 our group
has demonstrated no signiﬁcant lymphopenia in 26 patients aged
62 to 86 years (median 73 years) undergoing radiotherapy for
high-risk prostate adenocarcinoma.13 In this study, complete
blood counts (CBCs) were retrospectively analyzed with differ-
ential data on prospectively collected blood samples. CBC data
were collected before radiotherapy and at up to 4 time points
thereafter (1-90 days, 91-180 days, 181-360 days, and > 360
days), and were compared with normal ranges from an outside
laboratory reference (white blood cell [WBC] count, 3800-10,700
cells/mL; absolute lymphocyte count [ALC], 910-4280 cells/mL).
Patients received conventional external beam radiotherapy (EBRT)
from 64.8 to 81.0 Gy in 1.8-Gy fractions, with a small number
receiving brachytherapy. Sixteen patients also received androgen
deprivation therapy.
Baseline cell counts were within normal ranges (Table 1).13
Counts decreased in the 3 months after radiotherapy, although
median values remained within the normal range. Thereafter,median WBC and then ALC increased gradually to 5800 and 1250
cells/mL, respectively, approximately 6 to 12 months after radio-
therapy (Figure 2).13 Thus, median WBC and ALC remained
within normal limits for the full follow-up period. These results
challenge the view that standard radiotherapy in high-risk prostate
adenocarcinoma is immunosuppressive. To be successful, immu-
notherapy requires an active immune system, and the stability of cellClinical Genitourinary Cancer February 2015 - 3
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combining radiation and immunotherapy.
Radiotherapy and Antitumor Immune Responses
Evidence shows that, in addition to treating a localized tumor,
radiotherapy can inﬂuence immune responses. For example,
tumor-speciﬁc immune responses have been reported after
radiotherapy in patients with prostate cancer.14,15 Nesslinger et al
examined serum samples before and after radiotherapy from
men with localized disease and found treatment-associated
autoantibody responses in 4 of 29 (13.8%) who had undergone
radiotherapy and 3 of 10 (30%) who had received brachytherapy,
which included autoantibody responses to serologically deﬁned
colon cancer antigen 1, outer dense ﬁber of sperm tails 2, and
poly [ADP-ribose] polymerase family, member 1.14 In another
study, Schaue et al found the expression of survivin-speciﬁc
cluster of differentiation (CD)8-positive (CD8þ) T cells in pe-
ripheral blood to increase with radiotherapy in 7 of 11 (63.6%)
prostate cancer patients.15 Increases in survivin-speciﬁc CD8þ T
cells were also seen in patients with colorectal cancer in this
study. Signiﬁcantly, the observed lack of immune tolerance to
survivin made immunotherapy combined with radiotherapy
feasible in these patients.15
Effects of Radiation Therapy That Might Inﬂuence
Immune Responses
When considering how radiotherapy could stimulate anticancer
immune responses, there is now known to be interplay between
tumor cell death, antigen expression, and inﬂammatory signals that
affect lymphocyte and DC activation.8,9 Indeed, numerous studies
have shown that targeted radiation can induce cellular expression of
a wide variety of immune factors with effects on different cell types,
as discussed in the following sections (see also Figure 1).
Major Histocompatibility Complex Class I. Major histocompati-
bility complex class I molecules bind cytosol-derived peptides
and present them at the cell surface, allowing CD8þ T cells to
recognize and potentially destroy transformed or virus-infected
cells.16 Localized irradiation of a wide variety of human tumor
cell lines can result in increased expression of MHC class I, Fas,
and ICAM-1.17 Upregulation of these cell surface molecules was
accompanied by signiﬁcantly enhanced tumor cell killing by
CD8þ cytotoxic T lymphocytes (CTLs). Furthermore, in vivo cell
surface expression of MHC class I molecules was shown in murine
adenocarcinoma cells to be dose-dependently increased for several
days after irradiation.18
Death Receptors. Fas is expressed at the cell surface in certain
circumstances and induces apoptosis within the cell when engaged
by the Fas ligand, which is present on activated T cell subsets.16
Therefore induction of Fas expression by tumor cells can facilitate
tumor cell killing by immune effectors. In a murine carcinoem-
bryonic antigen-speciﬁc CD8þ CTL tumor model, localized irra-
diation of tumors caused upregulation of Fas and potentiated tumor
rejection.19 In another study, sublethal irradiation of colorectal
carcinoma cell lines resulted in sensitization of tumor cells tonical Genitourinary Cancer February 2015Fas- and TNF-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis.20
Immunomodulatory Cytokines Such as IL and TNF-a. Expression
of the proinﬂammatory cytokine TNF-a was increased after radia-
tion exposure in a study of human sarcoma cells, with enhancement
of radiation lethality in TNF-aeproducing and enonproducing
cells.21 Radiation exposure has also been linked to expression of
IL-1b (involved in T cell and macrophage activation) and TNF-a
in mouse studies.22,23 Similarly, increased heat shock protein 72
expression has been linked to increases in circulating levels of IL-6
(involved in the acute phase response and antibody responses) and
TNF-a after irradiation in patients with prostate cancer.24
Adhesion Molecules. Intercellular adhesion molecule 1 (also
known as CD54) is an endothelial membrane protein that con-
tributes to leukocyte adherence to, and migration through, blood
vessel endothelia.16 This process, termed extravasation, is essential
for immune effector cells to exit the blood into the tissues to reach
the site of solid tumors. Irradiation of human dermal microvascular
endothelial cells caused dose-dependent increases in surface
expression and mRNA of ICAM-1.25
Co-Stimulatory Molecules. Expression of co-stimulatory B7
molecules by APCs contributes to T cell activation, and engage-
ment of T cells in the absence of co-stimulation can lead to im-
mune regulation and dampening of immune responses.16
Therefore, B7 expression is particularly relevant in the context
of myeloid leukemias, because key APCs are derived from the
myeloid lineage. Gamma irradiation of human acute myeloid
leukemia (AML) cells has been shown to result in induction of
B7.1 expression, and might therefore be capable of stimulating an
anti-AML immune response.26
The described molecular effects combine with other local effects
to inﬂuence immune responses. For example, radiation can induce
a proinﬂammatory microenvironment within tumors that provide
DCs with maturation-inducing stimuli.9 Cell death caused by
irradiation also results in extensive exposure of the lymphatic sys-
tem to tumor antigens through necrosis or apoptosis of tumor cells
and the subsequent release of cellular debris.27,28 Furthermore,
irradiation of DCs has been shown to inhibit endogenous antigen
processing while enhancing antigenic peptide presentation.29,30
DCs that had acquired antigen from apoptotic tumor cells were
in turn able to induce MHC class Ierestricted T cells and confer
antitumor immunity in a murine model.27 Molecular pathways
speciﬁcally activated during irradiation-induced cell death can also
be immunostimulatory.31 For example, dying tumor cells secrete
the high-mobility group box 1 (HMGB1) alarmin protein that acts
on toll-like receptor 4 expressed by DCs, thereby promoting efﬁ-
cient processing and presentation of antigens.32 HMGB1 effects on
DCs also include maturation changes and creation of a chronic
inﬂammatory state.33 In addition, the adhesion molecule effects on
stromal cells described previously increase the permeability of the
local vasculature that allows circulating leukocytes to inﬁltrate the
surrounding tissues.25 Remodeling of the vasculature in a proin-
ﬂammatory environment can permit T lymphocytes to extravasate
Steven E. Finkelstein et aland destroy tumor cells.34 In addition, tumor cells can be pheno-
typically modulated by radiation, which increases their susceptibility
to cell-killing.35 Taken together, these immunostimulatory effects
of radiation might at least partly explain the abscopal effect, in
which localized treatment with ionizing radiation can result in
reduction of tumor masses distant from the primary site.36 This
effect has been reported in 2 recent cases of metastatic melanoma
treated with radiotherapy and immunotherapy,37,38 demonstrating
that the combination of these 2 therapeutic approaches might
support the host immune response to tumor antigens.
Finally, when reviewing data on this subject it is important to
remember that there is a balance between suppressant and stim-
ulant effects on the immune system that depends on the dose,
fractionation, and targeting of radiotherapy.39,40 In addition to
providing a radiation-induced proinﬂammatory environment that
facilitates antigen presentation and other positive immunologic
effects, radiation can also promote the development of myeloid
cells, which facilitate tumor growth, and regulatory T cells, which
dampen or prevent immune responses.41,42 Thus, radiation can be
an immunoadjuvant in the right circumstances, but the response
reportedly varies with dose and fractionation.40 This offers possi-
bilities for reﬁning radiotherapy techniques so that they favor
stimulant effects.
Combination of Radiotherapy and
Immunotherapy for Prostate
Cancer
Discovery of the variety of immunostimulant effects resulting
from radiation treatment has increased interest in combining
immunotherapy with tumor irradiation to produce synergistic
beneﬁt in a range of cancers.1,35,43-46 The preclinical evidence for
synergy between radiotherapy and immunotherapy has been
reviewed recently by Kwilas et al45 and we therefore focus herein on
recent clinical data.
Immunotherapy in Prostate Cancer
New ﬁndings are constantly being made in animal models of
oncology immunotherapy, and these often have important impli-
cations for furthering immunotherapy research in humans.47,48
Currently, a variety of immunotherapeutic treatments are available
or in development for use in prostate cancer. These include
sipuleucel-T, an autologous, APC-based immunotherapy that tar-
gets the immune response toward a deﬁned prostate antigen
(prostatic acid phosphatase [PAP]).49 Sipuleucel-T was the ﬁrst
cancer immunotherapy approved by the United States Food and
Drug Administration for the treatment of asymptomatic or mini-
mally symptomatic metastatic castration-resistant prostate cancer
(mCRPC)50 and by the European Medicines Agency for asymp-
tomatic or minimally symptomatic metastatic (nonvisceral)
castration-resistant prostate cancer in male adults in whom
chemotherapy was not yet clinically indicated.51 Approval was pri-
marily based on the phase III IMPACT (IMmunotherapy Prostate
AdenoCarcinoma Treatment) trial, which showed a 4.1-month
improvement in median survival over placebo (25.8 vs. 21.7
months).52 The relative reduction in risk of death was 22% with
sipuleucel-T (hazard ratio, 0.78; 95% conﬁdence interval, 0.61-
0.98; P ¼ .03). T cell and humoral immune responses to theprostate antigen were observed in patients receiving sipuleucel-T
and correlated with survival.53 These results and subsequent
approval are reﬂected in recent updates to National Comprehensive
Cancer Network guidelines for prostate cancer treatment, which
include the option of ﬁrst-line immunotherapy with sipuleucel-T in
men with mCRPC and good performance status (category 1;
Figure 3). The guidelines also emphasize the importance of radio-
therapy for patients with high-risk localized tumors, and clinical
practice has shown the value of EBRT and stereotactic body radi-
ation therapy, also known as stereotactic ablative radiotherapy, for
bone metastases.54-56
Prostate-speciﬁc antigen (PSA)-TRICOM (a recombinant viral
vaccine mixture encoding PSA with B7.1, ICAM-1, and leukocyte
functional antigen-3), ipilimumab (a fully human monoclonal
antibody against cytotoxic T-lymphocyte antigen [CTLA]-4), and
various peptides, proteins, and tumor antigens alone or linked to
viruses or co-stimulatory molecules are currently being investigated
in prostate cancer.57
Recent Progress with Combination Therapy
Notably, 2 recent studies have combined radiotherapy and
immunotherapy to good effect in patients with prostate cancer.
The ﬁrst was a pilot study of intraprostatic injection of autologous
DCs combined with EBRT and brachytherapy in 5 men with
localized tumors without radiologically evident metastases but with
high risk of recurrence (Table 2).58-60 In this study, serial prostate
biopsies consistently showed limited levels of lymphocytic inﬁl-
tration. No temporal inﬁltrate pattern linked to radiation or DC
injection was evident. The theoretically optimal time to inject
DCs into the tumor environment would be when apoptosis is
proceeding maximally, which was assessed in this study. However,
among tumor cores that were examined, there were up to 19%
of cells showing apoptosis. This small proportion reﬂects the dif-
ﬁculty in targeting a tumor using biopsies (the organ rather than
the tumor is targeted), and it therefore appears that the identiﬁ-
cation of time points at which radiation induces high rates of
apoptosis is not straightforward.
Functional T-cell responses before, during, and after treatment
were assessed by stimulating peripheral blood cells with prostate
tumor cell-derived peptides and measuring the number of inter-
feron-g-producing cells by enzyme-linked immunosorbent spot.
Tests showed a detectable increase from baseline in prostate-
speciﬁc T-cell responses in 2 of the 5 men. However, there was
no clear temporal pattern, baseline responses were detectable in
some men, and in some cases, strong responses to control peptides
were noted.
The technique used was feasible, well tolerated, and speciﬁc
immune responses were observed. However, the coordination of
apoptosis-inducing radiotherapy with autologous DC treatment
requires further study. In fact, a randomized phase II trial
(NCT01807065) is under way to assess the efﬁcacy of sipuleucel-
T in combination with radiotherapy in patients with mCRPC.
It should be noted that the treatment described herein58 differed
from sipuleucel-T therapy in the method of APC administra-
tion (intraprostatic injection vs. intravenous infusion), and also
in a lack of a deﬁned antigen (sipuleucel-T therapy directs the
immune response toward PAP). Similar approaches combiningClinical Genitourinary Cancer February 2015 - 5
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6 - Cliintratumoral DC injection with radiotherapy or chemotherapy for
sarcoma have shown promising preliminary results and warrant
further study.61,62
The second trial was a phase I/II study in men with mCRPC
that compared ipilimumab as monotherapy and in combination
with radiotherapy (Table 2).59 Ipilimumab is a fully human
monoclonal antibody that speciﬁcally blocks the binding of the
immunoregulatory molecule CTLA-4 to its ligands (CD80/CD86)Figure 3 Systemic Therapy for mCRPC. Abridged Summary of NCCN
Positive for Metastases.56
Sipuleucel-T Is Appropriate for Asymptomatic or Minimally Symptomatic Patients With Eastern Coope
Metastases or Life Expectancy < 6 Months.
yDocetaxel Can Be Used To Treat Patients With Rapid Progression or Asymptomatic Hepatic Metastase
zRadium-223 Is Not Approved for Use Combined With CT.
xFor Patients Unable to Receive Docetaxel; However, Although Mitoxantrone Is Included in the NCCN Gu
Abbreviations: CT ¼ Chemotherapy; HT ¼ Hormonal Therapy; mCRPC ¼ Metastatic Castration-Resi
nical Genitourinary Cancer February 2015and thereby augments T cell activation and proliferation.63 This
combination therapy study was carried out after initial trials
showed ipilimumab to have acceptable tolerability and antitumor
activity in patients with mCRPC.64,65 Of the 41 patients who
received combination therapy, 30, 8, and 3 had 1, 2, and 3 bone
lesions irradiated, respectively. Among patients who received 10
mg/kg with or without EBRT (n ¼ 34), 28 had evaluable tumors:
8 had PSA reductions of at least 50% ranging in duration fromGuideline for Patients With Advanced Disease Who Test
rative Oncology Group Performance Status 0 to 1, and Is Not Indicated for Patients With Hepatic
s, Because Asymptomatic and Symptomatic Patients Experience Survival Beneﬁt With Docetaxel.
idelines, Some Physicians No Longer Consider This Agent As Standard First- or Second-Line CT.
stant Prostate Cancer; NCCN ¼ National Comprehensive Cancer Network; RT ¼ Radiotherapy.
Table 2 Overview of Clinical Trials Evaluating Immunotherapy Combined With Radiation for Prostate Cancer
Citation Design Treatment Measurements Activity
Finkelstein et al, 201258 Nonrandomized, open-label
pilot study in 5 men with
localized tumors without
radiologically evident
metastases but with
high risk of recurrence
Twenty-eight months of androgen
suppression, 45 Gy of EBRT,
intraprostatic DC injection, and
brachytherapy seed placement.
Autologous DCs were obtained using
single-treatment apheresis and frozen.
Before reinfusion after radiation
fractions 5, 15, and 25, cells were
thawed and cultured in vitro for 4 days
with GM-CSF and IL-4
Interval biopsies and blood
tests were used to assess
immune reaction
Biopsies showed some apoptosis
(up to 19% in 11 tumor cores)
and limited lymphocytic inﬁltrates,
including CD8þ cells. Tests on
circulating lymphocytes showed
some instances of increased titers
to the test peptides
Slovin et al, 201359 Nonrandomized, open-label
phase I/II trial in 71 men
with mCRPC with disease
progression after
discontinuation of
antiandrogen therapy
and who had received
no more than 1 previous
course of chemotherapy
Comparison of ipilimumab monotherapy
(n ¼ 29; 3, 5, or 10 mg/kg given
every 3 weeks in a cycle of up to
4 doses) or ipilimumab (3 or 10 mg/kg)
in combination with EBRT (n ¼ 41).
EBRT was given as a single dose of
8 Gy per target bone lesion for up to
3 lesions per patient, 24 to 48 hours
before the ﬁrst ipilimumab dose.
Patients with disease progression after
an initial response (or stable disease)
could have up to 3 further ipilimumab
cycles, but no further EBRT
PSA decline and tumor
response
Among patients who received
ipilimumab 10 mg/kg with or
without EBRT (n ¼ 34), 28 had
evaluable tumors. Of these, 8 had
PSA reductions of at least 50%
(duration: 3 to 13 months).
There was 1 complete response
(observed in the EBRT group;
duration 11.3 months) and
6 patients had stable disease.
PSA changes were seen
irrespective of previous
chemotherapy
Kwon et al, 201460 Multicenter, randomized,
double-blind, phase III
trial in men with mCRPC
who had progressed after
docetaxel treatment
Patients were randomized to receive
bone-directed radiotherapy (8 Gy in
1 fraction) followed by either ipilimumab
10 mg/kg or placebo every 3 weeks for
up to 4 doses
Overall survival Median overall survival was 11.2
months with ipilimumab and 10.0
months with placebo (HR, 0.85;
95% CI, 0.72-1.00; P ¼ .053).
Prespeciﬁed analyses suggested
that ipilimumab might beneﬁt
some subgroups, particularly those
with favorable prognostic features
Abbreviations: DC ¼ dendritic cell; EBRT ¼ external beam radiation therapy; GM-CSF ¼ granulocyte-macrophage colony-stimulating factor; Gy ¼ Gray; HR ¼ hazard ratio; IL ¼ interleukin;
mCRPC ¼ metastatic castration-resistant prostate cancer; PSA ¼ prostate-speciﬁc antigen.
Steven E. Finkelstein et al3 to  13 months, there was 1 complete response (duration
 11.3 months), and 6 had stable disease.59 PSA changes were
seen irrespective of previous chemotherapy.59
However, a randomized phase III study (NCT00861614) in
patients with mCRPC whose disease had progressed after docetaxel
chemotherapy failed to show improved overall survival when ipili-
mumab was administered after radiotherapy compared with placebo
(Table 2).60 Future studies might also consider the combination of
radiotherapy and interferon, which has showed some promise in the
treatment of melanoma.66
Conclusion
The aim of cancer immunotherapy is to overcome the problem
of weak immunogenicity of tumor-associated antigenic material
and to provoke a robust immune response to cancer cells.
Conventionally, radiation has been perceived as immunosuppres-
sive, but recent experimental work shows that this is not necessarily
the case and radiotherapy can in fact have a variety of immunos-
timulatory effects. Emerging data thus show the potential for
radiotherapy to work synergistically with immunotherapy to
enhance antitumor immune responses, inhibit immunosuppres-
sion, and/or alter tumor cell phenotype to increase their suscep-
tibility to immune-mediated killing.45
The coordination of focal tumor irradiation and immuno-
therapy has the potential to maximize the beneﬁt of both treat-
ments in patients with prostate and other tumors. Augmentationof antitumor immune responses appears to be a logical and
promising approach, and the small-scale studies of radiotherapy
in combination with immunotherapy that have been carried
out to date support this view. mCRPC is one of few tumor
types in which immunotherapy is the current standard of care,57
and developments in combination therapy appear to be a logical
route toward future improvements in outlook for affected
patients.
Questions remain as to how best to exploit the full potential of
combination therapy. There might be variations in tumor micro-
environment, phenotype, and response brought about by differing
types of radiotherapy, and certain dosages and courses of radio-
therapy might be more beneﬁcial than others.45 There is also a
possibility that combination therapy might result in an increase in
the local control rate of prostate cancer; however, further studies are
required to clarify this. Optimization of the sequence and timing of
treatments should also assist with maximizing the efﬁcacy of radi-
ation combined with immunotherapy.57 The results of ongoing
studies investigating combinations of immunotherapies, such as
sipuleucel-T or nivolumab, after radiotherapy for the treatment of
prostate cancer are eagerly awaited.Acknowledgments
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